Clinical Practice Updates: Navigating the New Standard of Care in Bladder Cancer

Bladder cancer treatment has entered a period of unprecedented change, driven by the success of combination therapies in both the metastatic and localized settings. At the NCCN 2026 Annual Conference, updates to the clinical practice guidelines emphasized the movement of highly active agents, such as antibody-drug conjugates (ADCs), into earlier lines of therapy.

Thomas W. Flaig, MD, vice chancellor for research for CU Denver | Anschutz, explained that the focus has transitioned from simply offering more options to identifying the optimal sequence and timing for these potent therapies. This includes a growing emphasis on neoadjuvant strategies and the management of next-generation side effects, such as peripheral neuropathy and dermatologic reactions.

Transcript:

It is a very exciting time in bladder cancer right now. If you look at the NCCN Guidelines from just a few years ago compared to where they are today, the difference is truly remarkable. We have seen a massive influx of new drug classes, particularly antibody-drug conjugates and immunotherapies, which have fundamentally changed our expectations for patient outcomes. In the metastatic setting, the combination of enfortumab vedotin (Padcev) and pembrolizumab (Keytruda) has set a new benchmark for frontline therapy, providing survival benefits that we simply hadn't seen with traditional platinum-based chemotherapy alone.

One of the most significant shifts we are discussing here at the 2026 conference is how we take these successes from the metastatic space and move them earlier into the disease process. We are looking closely at the neoadjuvant setting for muscle-invasive bladder cancer. The goal is to use these highly active ADCs and immune checkpoint inhibitors before surgery to increase the rate of pathological complete response. This isn't just about shrinking the tumor; it’s about systemic control and potentially sparing some patients from the more aggressive morbidities associated with late-stage interventions.

However, with these new standards comes a new set of challenges for the clinical team. These drugs don't behave like the gemcitabine and cisplatin regimens we’ve used for decades. We are seeing unique toxicities—things like severe skin rashes, peripheral neuropathy, and even ocular issues—that require very proactive management. The NCCN Guidelines are evolving to not only recommend these drugs but to provide the framework for managing these toxicities so that patients can stay on therapy long enough to derive the full clinical benefit.

Looking forward, the focus is really on personalization. We are beginning to understand which patients benefit most from specific sequences of therapy. Whether it is the 'watch and wait' approach in certain responders or the use of targeted agents for specific mutations, the field is moving toward a more nuanced, precision-medicine approach. It is a complex landscape, but for the first time in a long time, we have the tools to significantly extend the lives of our patients with bladder cancer.

Transcript has been edited for clarity.